Medtronic, Merck roll out reorgs, shuffle leadership

Share this article:
Medtronic is consolidating its business into two operating groups – one focused on its heart rhythm and cardiovascular products, the other on everything else.
 
The reorganization comes as part of an initiative dubbed “One Medtronic." Under the new structure, Chris O'Connell, formerly head of the device giant's diabetes business, will lead the Spinal and Biologics, Neuromodulation, Diabetes and Surgical Technologies Group. Reporting to O'Connell will be Bob Blankemeyer, head of surgical technologies, Steve La Neve, head of spinal and biologics, Katie Szyman, head of Diabetes and Tom Tefft, head of Neuromodulation.

The company has not yet named someone to lead its Cardiac Rhythm Disease Management, CardioVascular and Physio-Control Group. Reporting to them will be Pat Mackin, head of CRDM, Scott Ward, head of Cardiovascular and Brian Webster, head of Physio-Control.

In addition, Jean-Luc Butel, formerly head of Medtronic International, will head International Operations, while Dr. Rick Kuntz will serve as SVP, chief scientific, clinical and regulatory officer. Kuntz previously headed Neuromodulation.

Meanwhile Merck announced a new organizational structure and leadership in the wake of its absorbtion of Schering-Plough. Merck chief Dick Clark will continue to lead the combined firm, which will have five primary divisions including:
  • Global Human Health, led by Merck's Kenneth Frazier
  • Animal Health, lead by Schering-Plough's Raul Kohan
  • Consumer Health Care, led by Schering-Plough's Stanley Barshay;
  • Merck Research Laboratories, led by Merck's Peter Kim
  • Merck Manufacturing, led by Merck's Willie Deese

Post-merger, Merck will also include new franchises focused on women's health and endocrine as well as mature brands, the firm said. About 40% of Schering-Plough's senior leaders will assume executive roles with the companied company.  

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...